-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|April 8, 2022

Residual Cardiovascular Risk

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

Episodes in this series

EP. 1 The Burden of ASCVD and Evidence-Based Guidelines

EP. 1 The Burden of ASCVD and Evidence-Based Guidelines

EP. 2 A Patient’s Post-MI Journey

EP. 2 A Patient’s Post-MI Journey

EP. 3 Improving the Care Continuum

EP. 3 Improving the Care Continuum

EP. 4 Residual Cardiovascular Risk

EP. 4 Residual Cardiovascular Risk

EP. 5 Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP. 5 Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP. 6 Finding the Optimal Statin Dose

EP. 6 Finding the Optimal Statin Dose

EP. 7 Therapy Beyond Statins in the Inpatient Setting

EP. 7 Therapy Beyond Statins in the Inpatient Setting

EP. 8 Using Adjunct Therapies in LDL Management

EP. 8 Using Adjunct Therapies in LDL Management

EP. 9 Ensuring Continuity of Care for the ASCVD Patient

EP. 9 Ensuring Continuity of Care for the ASCVD Patient

EP. 10 Unmet Needs in Lipid Management

EP. 10 Unmet Needs in Lipid Management

EP. 11 Defining “Optimal Care” for ASCVD Within Health Systems

EP. 11 Defining “Optimal Care” for ASCVD Within Health Systems

EP. 12 What Does a Multidisciplinary Team Look Like?

EP. 12 What Does a Multidisciplinary Team Look Like?

EP. 13 The Future of LDL Management for Patients With High-Risk ASCVD

EP. 13 The Future of LDL Management for Patients With High-Risk ASCVD

EP. 14 Enhancing Patient Care Through Guideline Adherence

EP. 14 Enhancing Patient Care Through Guideline Adherence

EP. 15 Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP. 15 Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP. 16 Appropriate ASCVD Treatment Outside of Closed Health Systems

EP. 16 Appropriate ASCVD Treatment Outside of Closed Health Systems

EP. 17 Utilizing Quality Metrics in ASCVD

EP. 17 Utilizing Quality Metrics in ASCVD

EP. 18 Improving Patient and Provider Engagement

EP. 18 Improving Patient and Provider Engagement

EP. 19 Treatment Disparities in the Management of ASCVD

EP. 19 Treatment Disparities in the Management of ASCVD

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

Remote Monitoring and Self-Efficacy: Implications for Breast Cancer Survivorship Outcomes